

OTC Markets Group

Joining us a day is Michael McFadden the CEO of Alpha Cognition Inc that trades on our OTCQB Venture Market under the ticker ACOGF based in Vancouver alpha cognition is a clinical stage biopharmaceutical company dedicated to developing treatments. For underserved neurodegenerative diseases such as Alzheimer's dementia and ALS. Michael thanks so much for joining us today Michael so give us some background about your professional experience and then how you got involved with alpha cognition.

Michael McFadden

My pleasure.

Michael McFadden

Sure so I've have about 30 years experience in biopharmaceutical companies all the way back to the 90 s my first decade I spent with large cap companies like Eli Lilly Pharmacy of Pfizer the last twenty years I've dedicated my time to startup companies. So these are pre-market companies bringing products over the finish line from an r and d perspective and then commercializing those products so about half my career has been in cns I felt like the startup and cns. Opportunity here at Alpha Cognition was a great fit for my experiences.

OTC Markets Group

Excellent and so what types of neurodegenerative diseases do you target in your programs with Alpha Cognition?

Michael McFadden

It' so great. Question. We have a late stage program targeted toward mild to moderate Alzheimer's dementia. We're actually in pivotal trial for that program and expect approval in 2023 we have 2 early stage programs one is targeting mild traumatic brain injury. That's a condition that affects about 3000000 people. There's no approved treatment for that condition and then we have a gene therapy program that's full length programnulin targeting a ALS is a rare neurodegenerative diseases. Ah, disease and it affects about 15000 people worldwide ah problem with that disease is there's no good treatment available for these patients and the morbidity on that disease is 100% so we're hopeful that we can advance our program for ALS this year

OTC Markets Group

And what clinical stages are your treatments in and how do they differ from your

Michael McFadden

So I'll talk about our lead program. We're in pivotal trial. So that's late stage for alpha 1062 that's a treatment for mild to moderate Alzheimer's our product has a multimodal receptor activity which differs it from some of the existing. Ah, currently approved products in that therapeutic arena and it would be if approved one of the only treatments approved in the last ten years to treat symptoms of Alzheimer's dementia and potentially. Have some other beneficial effects for patients caregivers and physicians.

OTC Markets Group

And why are diseases such as Alzheimer's and ALS so important to study and how do they impact our health care systems.

Michael McFadden

So I'll start with Alzheimer's. Alzheimer's is a very challenging disease it affects about 6000000 persons in the United States and over 10000000 worldwide. The disease is. Disruptive not only to the patient or person suffering from Alzheimer's but it's also highly disruptive to the family the caregiver and the friendship circle that that patient may ah participate in the disease is especially painful because it digresses the patient their ability to function. Their ability to remember their ability to do the normal daily activities that we take for granted and the disease often leads in almost every case to full-time care or in most countries, nursing home care institutionalization of. Person because they're unable to take care of themselves. So it's a significant disease and there's the challenge with the disease There's been no um, good improvements to therapy and not only one approved drug in the last ten or so years so it's a. Disease and need of new therapies and a disease and need of advancements in treatment now as I mentioned previously is one ah hundred percent morbid disease all patients end up passing from the disease and it also is devastating not only for patient and their family. It results in loss of ability to move and ultimately loss ability to swallow that there have been a few treatments approved for the disease but most of the clinical experts and the physicians who treat these patients say that there is significant need for new therapies that can tackle this deadly disease.

OTC Markets Group

And what milestones are you looking forward to in 2022

Michael McFadden

## Podcast

So 2022 is probably the most impactful year for alpha cognition. We have a number of milestone events that provide inflection points for investors we have release of our top line data in our mtbi trial. And release of data in our prograal and gene therapy trial both in Q1 of this year in Q2 we release top line data from our pivotal trial and will announce initiation of a patient tolerability study that will be used to enhance label and obtain pricing for our product and then later in the year we plan to file Nda for alpha 10 62 for Alzheimer's program and there are a number of other milestones that will be available to investors for our company.

OTC Markets Group

This very exciting alpha cognition began trading on the OTCQB Venture Market in the fall of 2021 and has also traded on the TSX-V. How are you leveraging your investor strategy here in the us with OTC Markets.

Michael McFadden

So one of the historical issues with our company. It's been a small company that's been independently financed or privately financed for many years hence many investors both in the US and the Canadian markets are still unaware of the company. And our extensive pipeline. So one of the initiatives that we've taken on ah over the last year is to inform investors about our programs educate them on the diseases that we're pursuing and also why they might choose to invest in alpha cognition. Based on the clinical advancements that we've already made and the inflection points that we have forthcoming so been very busy informing investors educating investors and also educating and talking to the analysts who cover the space so that they are aware of our company and our products.

OTC Markets Group

So well. Thanks for your time today. Michael it's been great talking with you.

Michael McFadden

That's great talking with you and for those who are interested in following our company. We're available on all social media. You can find us at <http://alphacognition.com> and if you're interested in talking with members of management team. You can certainly reach out to our investor relations.

OTC Markets Group

Alpha cognition trades under the symbol ACOGF on our OTCQB Venture Market.



Podcast

Alpha Cognition Inc.  
Season 6 | Episode 7

---

*\*This is an autogenerated transcript and may contain typos.*